These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10804314)

  • 1. [Health economics, pharmacoeconomics and prescriptions in dermatology].
    Berdeaux G
    Ann Dermatol Venereol; 2000 Mar; 127(3):324-8. PubMed ID: 10804314
    [No Abstract]   [Full Text] [Related]  

  • 2. Infliximab for the treatment of extensive plaque psoriasis--regulation, cost and reimbursement.
    Rabinovich M; Fainaru M
    Isr Med Assoc J; 2003 Nov; 5(11):817-8. PubMed ID: 14650110
    [No Abstract]   [Full Text] [Related]  

  • 3. [Pharmaceutical organization recommends to budget-concerned physicians: simply do without some prescriptions!].
    Vorderwulbecke U
    MMW Fortschr Med; 1999 Dec; 141(48):56. PubMed ID: 10766549
    [No Abstract]   [Full Text] [Related]  

  • 4. The pharmacoeconomics of acne treatment: where are we heading?
    Inglese MJ; Fleischer AB; Feldman SR; Balkrishnan R
    J Dermatolog Treat; 2008; 19(1):27-37. PubMed ID: 18273722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fewer prescriptions, but higher costs. For this physicians might be punished!].
    MMW Fortschr Med; 2002 Jun; 144(26):51. PubMed ID: 12154478
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health economics studies in dermatology].
    Rogalski C; Simon J; Paasch U
    Hautarzt; 2006 Apr; 57(4):297-302. PubMed ID: 15971088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fear of retrospective data initiative. Bavarian physicians stream into the medication program].
    MMW Fortschr Med; 2005 Jul; 147(27-28):49. PubMed ID: 16041946
    [No Abstract]   [Full Text] [Related]  

  • 9. [Do pharmacists and the state increase drug costs?].
    Kaesback W
    MMW Fortschr Med; 1999 Dec; 141(48):54. PubMed ID: 10766548
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug expenditure in Ireland 1991-2001.
    Barry M
    Ir Med J; 2002; 95(10):294-5. PubMed ID: 12537322
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug expenditures and health insurance contributions increase. Control of budgetsis at risk].
    Jentsch P
    MMW Fortschr Med; 2001 Jul; 143(26-27):49-50. PubMed ID: 11481918
    [No Abstract]   [Full Text] [Related]  

  • 12. [Unfairly implicated as cost drivers. New drugs without a chance?].
    MMW Fortschr Med; 2004 Mar; 146(10):45. PubMed ID: 15347085
    [No Abstract]   [Full Text] [Related]  

  • 13. A Policy-Driven Perspective on Rising Drug Costs in Dermatology.
    Nguyen HP; Forman HP
    JAMA Dermatol; 2016 Jun; 152(6):625-6. PubMed ID: 27008060
    [No Abstract]   [Full Text] [Related]  

  • 14. [[Prescriptions for psychotropic drugs: results and comments on the 2007 prescription drug report].
    Fritze J
    Nervenarzt; 2008 Nov; 79(11):1337-45. PubMed ID: 19002733
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prescriptions for psychotropic drugs: results and comments on the 2005 prescription drug report].
    Fritze J
    Nervenarzt; 2006 Mar; 77(3):376-83. PubMed ID: 17078120
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lean years for patients].
    Klose G; Anlauf M
    MMW Fortschr Med; 2004 Dec; 146(51-52):16. PubMed ID: 15675237
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on "Where's the value in health care"?
    Lungen M; Gerber A
    Value Health; 2007; 10(2):170; author reply 171. PubMed ID: 17391426
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pharmacotherapy of hypertension. How much can safely be saved?].
    Anlauf M
    MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022
    [No Abstract]   [Full Text] [Related]  

  • 19. [Experiences with drug control in public health insurance medicine. Costs increase further and care becomes poorer].
    MMW Fortschr Med; 2003 Jul; 145(29-30):57. PubMed ID: 12958782
    [No Abstract]   [Full Text] [Related]  

  • 20. [New drugs in Spain -- when are they to be considered cost-effective alternatives and profitable investments for the National Health System? ].
    Soto Alvarez J
    Farm Hosp; 2004; 28(4):299-304. PubMed ID: 15369442
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.